Our Bureau Drugmakers Roche Pharma India and Cipla have entered into a distribution agreement for rheumatoid arthritis drug tocilizumab (Actemra) and Syndyma, the second brand of Roche’s cancer therapy bevacizumab (Avastin), in India .
The two companies have, in the past, locked horns legally. But the latest distribution agreement is aimed at increasing access to innovative medicines in India, a note from the companies said.
Lara Bezerra, Roche (India) Managing Director, said the partnership will help Roche focus on bringing new, transformative medicines to patients in India. “At Roche, we will continue to collaborate with various stakeholders to help transform healthcare in India,” she said in a note from the company.
Umang Vohra, Cipla Managing Director and Global Chief Executive, said: “The prevalence of cancer and rheumatoid arthritis is wide... across India, and Cipla can contribute to provide broader access to innovative medicines like tocilizumab and bevacizumab .”
Both drugs are biologic products or complex drugs made from living organisms.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.